Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 2/20 | 0.72 |
| ▸ | ADRB2 | P07550 | 18/20 | 0.67 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.67 |
| ▸ | PDE4A | P27815 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7791110 | 0.99 | ABCB11 (0.71) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| SCHEMBL8528222 | 0.88 | ABCB11 (0.74) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| Hydrochloric Acid SCHEMBL8532220 | 0.88 | ABCB11 (0.73) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| SCHEMBL8528403 | 0.87 | ABCB11 (0.93) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| SCHEMBL7795607 | 0.87 | ADRB2 (0.58) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| SCHEMBL4535621 | 0.87 | ADRB2 (0.83) | ABCB11ADRB2ADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL8527365 | 0.86 | ABCB11 (0.92) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| Carboxynaphthol SCHEMBL8533680 | 0.85 | ABCB11 (0.74) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| Cadaverine Tartrate SCHEMBL8527693 | 0.82 | ABCB11 (0.83) | ABCB11ADRB2ADRB1DRD2PDE4A | |
| SCHEMBL7842148 | 0.82 | ADRB2 (0.63) | ABCB11ADRB2ADRB1DRD2PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163672-B2 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | claimed |
| JP-2007500254-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1646691-A1 | QUINACRIDONE PIGMENT COMPOSITIONS COMPRISING UNSYMMETRICALLY SUBSTITUTED COMPONENTS | Ciba SC Holding AG (CH) | 2006-04-19 | — | — | EP | claimed |
| EP-1345591-B1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2005-03-02 | — | — | EP | claimed |
| WO-2005014728-A1 | QUINACRIDONE PIGMENT COMPOSITIONS COMPRISING UNSYMMETRICALLY SUBSTITUTED COMPONENTS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2005-02-17 | — | — | WO | claimed |
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | claimed |
| EP-1345591-A1 | PHARMACEUTICAL AEROSOL FORMULATION | AstraZeneca AB (SE) | 2003-09-24 | — | — | EP | claimed |
| WO-2002049616-A1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2002-06-27 | — | — | WO | claimed |
| US-7163672-B2 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2007-01-16 | — | — | US | disclosed |
| EP-1735270-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005070877-A1 | DIAMINO ALCOHOLS AND THEIR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| EP-1345591-B1 | PHARMACEUTICAL AEROSOL FORMULATION | ASTRAZENECA AB (SE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ASTRAZENECA AB (SE) | 2004-04-29 | — | — | US | disclosed |
| WO-1997045422-A1 | ANTI-NEURODEGENERATIVELY EFFECTIVE 10-AMINOALIPHATYL-DIBENZ[b,f]OXEPINE SALTS | NOVARTIS AG (CH) | 1997-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082520-A1 | Pharmaceutical aerosol formulation | ALG1, ALG8, DDOST | ABCB11 319/4885ADRB2 64/4885ADRB1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.